Alumis and Acelyrin have filed a definitive proxy statement/prospectus with the US Securities and Exchange Commission for the ...

Nordic Pharma plans to announce commercialization details in the near future for the dry eye disease treatment ...

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the last 5 decades.

The decision to discontinue the trials comes shortly after the announcement that COAST missed its primary endpoint.

Labtician Ophthalmics has announced the commercial launch of Lab TRIACTIV, an artificial tear designed to redefine dry eye ...

Recent estimates show that there are over 2 billion users on Instagram, of which over 726.8 million interact with reels on ...

Andrew G. Lee, MD, and Drew Carey, MD, return for this episode of 'NeuroOp Guru' to discuss how sixth nerve palsy with ...

The trial is designed to assess the safety and effectiveness of Avisi Technologies' investigational VisiPlate device in ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

The company stated that the FDA noted at least one additional adequate and well controlled study to demonstrate a positive ...

The approval makes ILM-Blue the first DORC posterior dye product available in China, according to a press release from Zeiss.

The May 4 event, themed around Star Wars, will feature the latest innovations, foster open discussions, and provide a ...